The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT) and ...

People have to test negative for HIV before they can receive the shot, which is administered under the skin of the abdomen. There are an estimated 30,000 new HIV infections in the U.S. annually.

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

Why FDA approval of new HIV prevention drug is a big deal The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.

HIV's route to infection is more flexible than previously believed, study finds by Emily Kagey, Morgan Sherburne, University of Michigan edited by Lisa Lock, reviewed by Robert Egan Editors' notes ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s ...

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more t… ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

In 2012, the FDA approved Truvada, also made by Gilead Sciences, making it the first PrEP medication for HIV prevention in uninfected adults in the United States – but “even though PrEP has ...

The drug, lenacapavir, will be sold under the name Yeztugo. “This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in a press release.